ImmunityBio (IBRX) Projected to Release Quarterly Earnings on Tuesday

Key Points

• ImmunityBio is expected to report Q3 2026 results before the market opens Tuesday, November 3. Analysts anticipate a loss of $0.07 per share on $59.23 million in revenue; the earnings call is scheduled for November 6.
• The company previously missed earnings expectations, reporting a $0.22-per-share loss versus the expected $0.08 loss, though revenue of $51.24 million exceeded estimates. IBRX shares opened at $7.81 and were reported down 5%.
• Analyst sentiment remains mostly positive, with six Buy ratings and one Sell rating producing a “Moderate Buy” consensus and a $16 target price. Two directors recently sold shares under pre-arranged trading plans, while insiders collectively own 66.1% of the company.

ImmunityBio (NASDAQ:IBRX - Get Free Report) is expected to be issuing its Q3 2026 results before the market opens on Tuesday, November 3rd. Analysts expect ImmunityBio to post earnings of ($0.07) per share and revenue of $59.23 million for the quarter. Individuals may review the information on the company's upcoming Q3 2026 earnings report for the latest details on the call scheduled for Friday, November 6, 2026 at 9:30 AM ET.

ImmunityBio (NASDAQ:IBRX - Get Free Report) last issued its quarterly earnings results on Tuesday, August 4th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million during the quarter, compared to analysts' expectations of $49.70 million. On average, analysts expect ImmunityBio to post ($0.30) EPS for the current fiscal year and ($0.11) EPS for the next fiscal year.

ImmunityBio Trading Down 5.0%

IBRX stock opened at $7.81 on Tuesday. The company's 50 day moving average is $8.65 and its 200 day moving average is $7.73. The stock has a market cap of $8.28 billion, a price-to-earnings ratio of -8.05 and a beta of 0.02. ImmunityBio has a 1-year low of $1.95 and a 1-year high of $12.43.

Insider Buying and Selling

In other ImmunityBio news, Director Cheryl Cohen sold 81,056 shares of the stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $10.50, for a total transaction of $851,088.00. Following the transaction, the director directly owned 100,309 shares in the company, valued at $1,053,244.50. This trade represents a 44.69% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of the stock in a transaction that occurred on Monday, October 5th. The shares were sold at an average price of $10.75, for a total transaction of $268,750.00. Following the transaction, the director owned 2,777,788 shares in the company, valued at $29,861,221. The trade was a 0.89% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 66.10% of the company's stock.

Analyst Ratings Changes

IBRX has been the subject of several research analyst reports. Piper Sandler reiterated an "overweight" rating and set a $16.00 target price on shares of ImmunityBio in a research report on Wednesday, October 14th. Weiss Ratings reissued a "sell (d-)" rating on shares of ImmunityBio in a report on Tuesday, October 6th. Jefferies Financial Group increased their price target on shares of ImmunityBio from $12.00 to $14.00 and gave the stock a "buy" rating in a report on Wednesday, October 14th. Finally, HC Wainwright restated a "buy" rating and set a $15.00 price objective on shares of ImmunityBio in a research report on Thursday, October 15th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, ImmunityBio currently has a consensus rating of "Moderate Buy" and a consensus target price of $16.00.

ImmunityBio Company Profile

ImmunityBio, Inc is a biotechnology company focused on developing and commercializing immunotherapies designed to activate and strengthen the body's immune response against cancer and infectious diseases. The company's approach combines immune-system modulators, cellular therapies, vaccines and other technologies intended to address multiple stages of the disease-treatment process.

Its lead product, Anktiva (nogapendekin alfa inbakicept-pmln, also known as N-803), is an interleukin-15 receptor agonist designed to stimulate natural killer cells and T cells.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.